Dear ASCCT members,
I’m sending this on behalf of one of our members, Dr. Sandra Reynoso, as many
of you may find this webinar useful.
And, this is a good time to remind you of the ASCCT webinar program. If you
have ideas for webinars you would like to see or would like to give a webinar
yourself, please let us know.
Genomics - the future of sensitization testing and assessment
Join us for a webinar on Sep 22, 2016 at 1:00 PM EDT.
This free webinar will focus on In vitro testing in human cell lines using
genomics technology being the future in safety testing of chemicals and
SenzaGen is presenting their use of genomics for sensitization testing with
GARD assays for skin and respiratory sensitization. Using +200 biomarkers
enables better predictions, including potency information.
In the webinar we will present the novel in vitro testing platform, called GARD
- Genomic Allergen Rapid Detection, for the prediction of sensitizing
chemicals, based on differential expression of disease-associated genomic
biomarkers in human myeloid dendritic cell-like cells. To date, applications of
the GARD platform have generated GARDskin, a novel, state of the art assay for
the assessment of chemical skin sensitizers, exhibiting superior predictive
performance compared to both in vivo and in vitro counterparts. The platform is
further developed for respiratory sensitization and is showing good potential
for predicting the potency of a chemical
This webinar will cover and describe the following:
• Development, scientific validation, applications and the current state of the
• The scientific rationale behind the use of genomic biomarker signatures
• Possible potency classification
• Links to the AOP in a biological context
• Advantages realized through multivariate computational prediction models in a
After registering, you will receive a confirmation email containing information
about joining the webinar.